IGX Share Price

Open 1.00 Change Price %
High 1.00 1 Day -0.08 -8.00
Low 0.92 1 Week -0.12 -11.54
Close 0.92 1 Month -0.04 -4.17
Volume 13950 1 Year 0.24 35.29
52 Week High 1.35
52 Week Low 0.55
IGX Important Levels
Resistance 2 0.99
Resistance 1 0.96
Pivot 0.95
Support 1 0.88
Support 2 0.85
CVE Canada Most Active Stocks
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
FO 0.07 0.00%
FO 0.07 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
DVN 0.17 0.00%
More..
CVE Canada Top Gainers Stocks
VRS 0.04 100.00%
VRS 0.04 100.00%
GV 0.02 100.00%
GV 0.02 100.00%
AZU 0.02 100.00%
AZU 0.02 100.00%
BVQ 0.02 100.00%
NAI 0.02 100.00%
NAI 0.02 100.00%
NAI 0.02 100.00%
More..
CVE Canada Top Losers Stocks
VEL 0.00 -100.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
SKK 0.12 -33.33%
More..

Intelgenx Technologies Corp. (CVE: IGX)

IGX Technical Analysis 1.5
As on 8th Dec 2016 IGX Share Price closed @ 0.92 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.80 & Sell for SHORT-TERM with Stoploss of 0.97 we also expect STOCK to react on Following IMPORTANT LEVELS.
IGX Target for December
1st Target up-side 1.21
2nd Target up-side 1.32
3rd Target up-side 1.43
1st Target down-side 0.89
2nd Target down-side 0.78
3rd Target down-side 0.67
IGX Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.intelgenx.com
IGX Address
IGX
6425 Abrams
Ville Saint Laurent, QC H4S 1X9
Canada
Phone: 514-331-7440
Fax: 514-331-0436
Interactive Technical Analysis Chart Intelgenx Technologies Corp. ( IGX CVE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Intelgenx Technologies Corp.
IGX Business Profile
IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. Its product portfolio comprises INT0001/2004 for coronary heart failure and hypertension; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2007 for the treatment of migraine; INT0024/2010 for idiopathic pulmonary fibrosis; INT0027/2011 for opioid dependence; INT0028/2011 for cancer pain; INT0030/2011 for animal health; and INT0036/2012 for central nervous system disorders, as well as INT0037/2013 and INT0039/2013. The company develops its products based on three delivery platform technologies, which consist of the Multilayer Tablet technology that allows for the development of oral controlled-release products; the Oral Film technology, which allows for the delivery of pharmaceuticals to the oral cavity; and the Mucoadhesive Tablet technology for the controlled release of active substances to the oral mucosa. It also provides product development services for the pharmaceutical industry, including the branded and generic pharmaceutical markets. The company has a strategic alliance with LTS Lohmann Therapie-Systeme AG to manufacture pharmaceutical products using VersaFilm drug delivery technology; and a strategic manufacturing partnership with Pillar5 Pharma Inc. IntelGenx Technologies Corp. also has a co-development and commercialization agreement with RedHill Biopharma Ltd. for the co-development and commercialization of INT0008/2007. IntelGenx Technologies Corp. was founded in 2003 and is based in Ville Saint Laurent, Canada.